Global Prescription Medicine 麻豆原创 Research Report 2024

Publication ID:

PB502250629

Publication Date:

March 8, 2024

Pages:

100

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global Prescription Medicine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Prescription Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Prescription Medicine.
Report Scope
The Prescription Medicine market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Prescription Medicine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Prescription Medicine companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Pfizer
Roche
Novartis
Johnson & Johnson
Merck & Co.
Sanofi
AbbVie
GlaxoSmithKline
Amgen
Gilead Science
Bristol-Myers Squibb
AstraZeneca
Eli Lilly
Bayer
Novo Nordisk
Takeda
Boehringer-Ingelheim
Allergan
Teva Pharmaceutical Industries
Mylan
Astellas Pharma
Biogen
CSL
Daiichi Sankyo
Otsuka Holdings
UCB
LES LABORATOIRES SERVIER
Bausch Health Companies
Eisai
Abbott Laboratories
Segment by Type
Original Brand Drug
Generic Drug
Segment by Application
Hospital
Clinic
Online
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Prescription Medicine companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Prescription Medicine 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Original Brand Drug
1.2.3 Generic Drug
1.3 麻豆原创 by Application
1.3.1 Global Prescription Medicine 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Online
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Prescription Medicine 麻豆原创 Perspective (2019-2030)
2.2 Prescription Medicine Growth Trends by Region
2.2.1 Global Prescription Medicine 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Prescription Medicine Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Prescription Medicine Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Prescription Medicine 麻豆原创 Dynamics
2.3.1 Prescription Medicine Industry Trends
2.3.2 Prescription Medicine 麻豆原创 Drivers
2.3.3 Prescription Medicine 麻豆原创 Challenges
2.3.4 Prescription Medicine 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Prescription Medicine Players by Revenue
3.1.1 Global Top Prescription Medicine Players by Revenue (2019-2024)
3.1.2 Global Prescription Medicine Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Prescription Medicine 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Prescription Medicine Revenue
3.4 Global Prescription Medicine 麻豆原创 Concentration Ratio
3.4.1 Global Prescription Medicine 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Prescription Medicine Revenue in 2023
3.5 Prescription Medicine Key Players Head office and Area Served
3.6 Key Players Prescription Medicine Product Solution and Service
3.7 Date of Enter into Prescription Medicine 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Prescription Medicine Breakdown Data by Type
4.1 Global Prescription Medicine Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Prescription Medicine Forecasted 麻豆原创 Size by Type (2025-2030)
5 Prescription Medicine Breakdown Data by Application
5.1 Global Prescription Medicine Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Prescription Medicine Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Prescription Medicine 麻豆原创 Size (2019-2030)
6.2 North America Prescription Medicine 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Prescription Medicine 麻豆原创 Size by Country (2019-2024)
6.4 North America Prescription Medicine 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Prescription Medicine 麻豆原创 Size (2019-2030)
7.2 Europe Prescription Medicine 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Prescription Medicine 麻豆原创 Size by Country (2019-2024)
7.4 Europe Prescription Medicine 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Prescription Medicine 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Prescription Medicine 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Prescription Medicine 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Prescription Medicine 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Prescription Medicine 麻豆原创 Size (2019-2030)
9.2 Latin America Prescription Medicine 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Prescription Medicine 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Prescription Medicine 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Prescription Medicine 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Prescription Medicine 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Prescription Medicine 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Prescription Medicine 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Prescription Medicine Introduction
11.1.4 Pfizer Revenue in Prescription Medicine Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Prescription Medicine Introduction
11.2.4 Roche Revenue in Prescription Medicine Business (2019-2024)
11.2.5 Roche Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Prescription Medicine Introduction
11.3.4 Novartis Revenue in Prescription Medicine Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Detail
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Prescription Medicine Introduction
11.4.4 Johnson & Johnson Revenue in Prescription Medicine Business (2019-2024)
11.4.5 Johnson & Johnson Recent Development
11.5 Merck & Co.
11.5.1 Merck & Co. Company Detail
11.5.2 Merck & Co. Business Overview
11.5.3 Merck & Co. Prescription Medicine Introduction
11.5.4 Merck & Co. Revenue in Prescription Medicine Business (2019-2024)
11.5.5 Merck & Co. Recent Development
11.6 Sanofi
11.6.1 Sanofi Company Detail
11.6.2 Sanofi Business Overview
11.6.3 Sanofi Prescription Medicine Introduction
11.6.4 Sanofi Revenue in Prescription Medicine Business (2019-2024)
11.6.5 Sanofi Recent Development
11.7 AbbVie
11.7.1 AbbVie Company Detail
11.7.2 AbbVie Business Overview
11.7.3 AbbVie Prescription Medicine Introduction
11.7.4 AbbVie Revenue in Prescription Medicine Business (2019-2024)
11.7.5 AbbVie Recent Development
11.8 GlaxoSmithKline
11.8.1 GlaxoSmithKline Company Detail
11.8.2 GlaxoSmithKline Business Overview
11.8.3 GlaxoSmithKline Prescription Medicine Introduction
11.8.4 GlaxoSmithKline Revenue in Prescription Medicine Business (2019-2024)
11.8.5 GlaxoSmithKline Recent Development
11.9 Amgen
11.9.1 Amgen Company Detail
11.9.2 Amgen Business Overview
11.9.3 Amgen Prescription Medicine Introduction
11.9.4 Amgen Revenue in Prescription Medicine Business (2019-2024)
11.9.5 Amgen Recent Development
11.10 Gilead Science
11.10.1 Gilead Science Company Detail
11.10.2 Gilead Science Business Overview
11.10.3 Gilead Science Prescription Medicine Introduction
11.10.4 Gilead Science Revenue in Prescription Medicine Business (2019-2024)
11.10.5 Gilead Science Recent Development
11.11 Bristol-Myers Squibb
11.11.1 Bristol-Myers Squibb Company Detail
11.11.2 Bristol-Myers Squibb Business Overview
11.11.3 Bristol-Myers Squibb Prescription Medicine Introduction
11.11.4 Bristol-Myers Squibb Revenue in Prescription Medicine Business (2019-2024)
11.11.5 Bristol-Myers Squibb Recent Development
11.12 AstraZeneca
11.12.1 AstraZeneca Company Detail
11.12.2 AstraZeneca Business Overview
11.12.3 AstraZeneca Prescription Medicine Introduction
11.12.4 AstraZeneca Revenue in Prescription Medicine Business (2019-2024)
11.12.5 AstraZeneca Recent Development
11.13 Eli Lilly
11.13.1 Eli Lilly Company Detail
11.13.2 Eli Lilly Business Overview
11.13.3 Eli Lilly Prescription Medicine Introduction
11.13.4 Eli Lilly Revenue in Prescription Medicine Business (2019-2024)
11.13.5 Eli Lilly Recent Development
11.14 Bayer
11.14.1 Bayer Company Detail
11.14.2 Bayer Business Overview
11.14.3 Bayer Prescription Medicine Introduction
11.14.4 Bayer Revenue in Prescription Medicine Business (2019-2024)
11.14.5 Bayer Recent Development
11.15 Novo Nordisk
11.15.1 Novo Nordisk Company Detail
11.15.2 Novo Nordisk Business Overview
11.15.3 Novo Nordisk Prescription Medicine Introduction
11.15.4 Novo Nordisk Revenue in Prescription Medicine Business (2019-2024)
11.15.5 Novo Nordisk Recent Development
11.16 Takeda
11.16.1 Takeda Company Detail
11.16.2 Takeda Business Overview
11.16.3 Takeda Prescription Medicine Introduction
11.16.4 Takeda Revenue in Prescription Medicine Business (2019-2024)
11.16.5 Takeda Recent Development
11.17 Boehringer-Ingelheim
11.17.1 Boehringer-Ingelheim Company Detail
11.17.2 Boehringer-Ingelheim Business Overview
11.17.3 Boehringer-Ingelheim Prescription Medicine Introduction
11.17.4 Boehringer-Ingelheim Revenue in Prescription Medicine Business (2019-2024)
11.17.5 Boehringer-Ingelheim Recent Development
11.18 Allergan
11.18.1 Allergan Company Detail
11.18.2 Allergan Business Overview
11.18.3 Allergan Prescription Medicine Introduction
11.18.4 Allergan Revenue in Prescription Medicine Business (2019-2024)
11.18.5 Allergan Recent Development
11.19 Teva Pharmaceutical Industries
11.19.1 Teva Pharmaceutical Industries Company Detail
11.19.2 Teva Pharmaceutical Industries Business Overview
11.19.3 Teva Pharmaceutical Industries Prescription Medicine Introduction
11.19.4 Teva Pharmaceutical Industries Revenue in Prescription Medicine Business (2019-2024)
11.19.5 Teva Pharmaceutical Industries Recent Development
11.20 Mylan
11.20.1 Mylan Company Detail
11.20.2 Mylan Business Overview
11.20.3 Mylan Prescription Medicine Introduction
11.20.4 Mylan Revenue in Prescription Medicine Business (2019-2024)
11.20.5 Mylan Recent Development
11.21 Astellas Pharma
11.21.1 Astellas Pharma Company Detail
11.21.2 Astellas Pharma Business Overview
11.21.3 Astellas Pharma Prescription Medicine Introduction
11.21.4 Astellas Pharma Revenue in Prescription Medicine Business (2019-2024)
11.21.5 Astellas Pharma Recent Development
11.22 Biogen
11.22.1 Biogen Company Detail
11.22.2 Biogen Business Overview
11.22.3 Biogen Prescription Medicine Introduction
11.22.4 Biogen Revenue in Prescription Medicine Business (2019-2024)
11.22.5 Biogen Recent Development
11.23 CSL
11.23.1 CSL Company Detail
11.23.2 CSL Business Overview
11.23.3 CSL Prescription Medicine Introduction
11.23.4 CSL Revenue in Prescription Medicine Business (2019-2024)
11.23.5 CSL Recent Development
11.24 Daiichi Sankyo
11.24.1 Daiichi Sankyo Company Detail
11.24.2 Daiichi Sankyo Business Overview
11.24.3 Daiichi Sankyo Prescription Medicine Introduction
11.24.4 Daiichi Sankyo Revenue in Prescription Medicine Business (2019-2024)
11.24.5 Daiichi Sankyo Recent Development
11.25 Otsuka Holdings
11.25.1 Otsuka Holdings Company Detail
11.25.2 Otsuka Holdings Business Overview
11.25.3 Otsuka Holdings Prescription Medicine Introduction
11.25.4 Otsuka Holdings Revenue in Prescription Medicine Business (2019-2024)
11.25.5 Otsuka Holdings Recent Development
11.26 UCB
11.26.1 UCB Company Detail
11.26.2 UCB Business Overview
11.26.3 UCB Prescription Medicine Introduction
11.26.4 UCB Revenue in Prescription Medicine Business (2019-2024)
11.26.5 UCB Recent Development
11.27 LES LABORATOIRES SERVIER
11.27.1 LES LABORATOIRES SERVIER Company Detail
11.27.2 LES LABORATOIRES SERVIER Business Overview
11.27.3 LES LABORATOIRES SERVIER Prescription Medicine Introduction
11.27.4 LES LABORATOIRES SERVIER Revenue in Prescription Medicine Business (2019-2024)
11.27.5 LES LABORATOIRES SERVIER Recent Development
11.28 Bausch Health Companies
11.28.1 Bausch Health Companies Company Detail
11.28.2 Bausch Health Companies Business Overview
11.28.3 Bausch Health Companies Prescription Medicine Introduction
11.28.4 Bausch Health Companies Revenue in Prescription Medicine Business (2019-2024)
11.28.5 Bausch Health Companies Recent Development
11.29 Eisai
11.29.1 Eisai Company Detail
11.29.2 Eisai Business Overview
11.29.3 Eisai Prescription Medicine Introduction
11.29.4 Eisai Revenue in Prescription Medicine Business (2019-2024)
11.29.5 Eisai Recent Development
11.30 Abbott Laboratories
11.30.1 Abbott Laboratories Company Detail
11.30.2 Abbott Laboratories Business Overview
11.30.3 Abbott Laboratories Prescription Medicine Introduction
11.30.4 Abbott Laboratories Revenue in Prescription Medicine Business (2019-2024)
11.30.5 Abbott Laboratories Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Pfizer
Roche
Novartis
Johnson & Johnson
Merck & Co.
Sanofi
AbbVie
GlaxoSmithKline
Amgen
Gilead Science
Bristol-Myers Squibb
AstraZeneca
Eli Lilly
Bayer
Novo Nordisk
Takeda
Boehringer-Ingelheim
Allergan
Teva Pharmaceutical Industries
Mylan
Astellas Pharma
Biogen
CSL
Daiichi Sankyo
Otsuka Holdings
UCB
LES LABORATOIRES SERVIER
Bausch Health Companies
Eisai
Abbott Laboratories

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.